SCHEMBL751608

SCHEMBL751608

NC(Cc1ccc(OF)cc1)C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 3/20 0.65
SLC7A5 Q01650 3/20 0.62
PTGS1 P23219 3/20 0.61
ALPI P09923 1/20 0.61
PKM P14618 1/20 0.61
XIAP P98170 1/20 0.61
ITGB3 P05106 1/20 0.59
ITGA2B P08514 1/20 0.59
GRB2 P62993 1/20 0.57
HIF1A Q16665 4/20 0.53
ALOX15 P16050 3/20 0.53
KDM4E B2RXH2 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
USP2 O75604 1/20 0.53
EGFR P00533 1/20 0.53
LCK P06239 1/20 0.53
FYN P06241 1/20 0.53
ADORA3 P0DMS8 1/20 0.53
HTR2A P28223 1/20 0.53
PTGS2 P35354 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3510986 1.00 PTPN1 (0.65) PTPN1SLC7A5PTGS1ALPIPKM
SCHEMBL2310526 0.84 SLC7A5 (0.83) PTPN1SLC7A5PTGS1ALPIPKM
SCHEMBL5497934 0.84 SLC7A5 (0.65) PTPN1SLC7A5PTGS1ALPIPKM
SCHEMBL5497939 0.84 SLC7A5 (0.65) PTPN1SLC7A5PTGS1ALPIPKM
SCHEMBL13620420 0.83 PTPN1 (0.61) PTPN1SLC7A5PTGS1ALPIPKM
D-Fluoromethyltyrosine F-18 SCHEMBL14346426 0.83 ITGB3 (0.64) PTPN1SLC7A5PTGS1ALPIPKM
D-Fluoromethyltyrosine SCHEMBL14343162 0.83 ITGB3 (0.64) PTPN1SLC7A5PTGS1ALPIPKM
SCHEMBL14406929 0.83 PTPN1 (0.61) PTPN1SLC7A5PTGS1ALPIPKM
D-Fluoromethyltyrosine F-18 SCHEMBL15944856 0.83 ITGB3 (0.64) PTPN1SLC7A5PTGS1ALPIPKM
D-Fluoromethyltyrosine F-18 SCHEMBL14342997 0.83 ITGB3 (0.64) PTPN1SLC7A5PTGS1ALPIPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2876165-A1 Improved method for producing modifed target polypeptides ACIB GmbH (AT) 2015-05-27 EP claimed
US-20250242053-A1 RECOMBINANT THERAPEUTIC FMR1 CONSTRUCTS AND METHODS OF TREATING FRAGILE X SYNDROME AND RELATED DISORDERS THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) 2025-07-31 US disclosed
US-20250136651-A1 RECOMBINANT OPTIMIZED MECP2 CASSETTES AND METHODS FOR TREATING RETT SYNDROME AND RELATED DISORDERS THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) 2025-05-01 US disclosed
EP-4514980-A1 RECOMBINANT THERAPEUTIC FMR1 CONSTRUCTS AND METHODS OF TREATING FRAGILE X SYNDROME AND RELATED DISORDERS The University Court Of The University of Edinburgh (GB) 2025-03-05 EP disclosed
WO-2023114816-A9 RECOMBINANT OPTIMIZED GALC CONSTRUCTS AND METHODS FOR TREATING GALC-ASSOCIATED DISORDERS NEUROGENE INC. (US) 2025-01-16 WO disclosed
CN-119301258-A Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders 爱丁堡大学董事会 2025-01-10 CN disclosed
EP-4473121-A1 RECOMBINANT OPTIMIZED MECP2 CASSETTES AND METHODS FOR TREATING RETT SYNDROME AND RELATED DISORDERS The University Court Of The University of Edinburgh (GB) 2024-12-11 EP disclosed
CN-118696126-A Recombinant optimized MECP2 cassettes and methods for treating Rate syndrome and related disorders 爱丁堡大学董事会 2024-09-24 CN disclosed
WO-2023209364-A1 RECOMBINANT THERAPEUTIC FMR1 CONSTRUCTS AND METHODS OF TREATING FRAGILE X SYNDROME AND RELATED DISORDERS THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) 2023-11-02 WO disclosed
WO-2023144565-A1 RECOMBINANT OPTIMIZED MECP2 CASSETTES AND METHODS FOR TREATING RETT SYNDROME AND RELATED DISORDERS THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) 2023-08-03 WO disclosed
US-20140193880-A1 MODIFIED FACTOR VIII AND FACTOR IX GENES AND VECTORS FOR GENE THERAPY ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) 2014-07-10 US disclosed
US-8632765-B2 Modified factor VIII and factor IX genes and vectors for gene therapy Asklepios Biopharmaceuticals, Inc. (US) 2014-01-21 US disclosed
WO-2013116244-A1 PRODUCTION OF MUCONIC ACID FROM GENETICALLY ENGINEERED MICROORGANISMS MYRIANT CORPORATION (US) 2013-08-08 WO disclosed
US-20130004462-A1 MODIFIED FACTOR VIII AND FACTOR IX GENES AND VECTORS FOR GENE THERAPY AskBio Inc. 2013-01-03 US disclosed
US-8198421-B2 Modified factor VIII and factor IX genes and vectors for gene therapy ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) 2012-06-12 US disclosed
WO-2012038444-A1 LIPASE CONGENERS WITH ENHANCED SUBSTRATE ACCESS Technische Universität Hamburg-Harburg (DE) 2012-03-29 WO disclosed
EP-2431461-A1 Lipase congeners with enhanced substrate access Technische Universität Hamburg-Harburg (DE) 2012-03-21 EP disclosed
US-20100284971-A1 MODIFIED FACTOR VIII AND FACTOR IX GENES AND VECTORS FOR GENE THERAPY ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) 2010-11-11 US disclosed
EP-2037892-A2 MODIFIED FACTOR VIII AND FACTOR IX GENES AND VECTORS FOR GENE THERAPY Asklepios Biopharmaceutical, Inc. (US) 2009-03-25 EP disclosed
WO-2007149852-A2 MODIFIED FACTOR VIII AND FACTOR IX GENES AND VECTORS FOR GENE THERAPY ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) 2007-12-27 WO disclosed